183 related articles for article (PubMed ID: 34373933)
1. Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis.
Tan C; Luo X; Li S; Yi L; Zeng X; Peng L; Qin S; Wang L; Wan X
Clin Rheumatol; 2022 Jan; 41(1):63-73. PubMed ID: 34373933
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity.
Prawjaeng J; Leelahavarong P; Budtarad N; Pilasant S; Chanjam C; Katchamart W; Narongroeknawin P; Kitumnuaypong T
BMC Health Serv Res; 2023 May; 23(1):561. PubMed ID: 37259090
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Triple Therapy vs. Biologic Treatment Sequence as First-line Therapy for Rheumatoid Arthritis Patients after Methotrexate Failure.
Li S; Li J; Peng L; Li Y; Wan X
Rheumatol Ther; 2021 Jun; 8(2):775-791. PubMed ID: 33772743
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of upadacitinib as a treatment option for patients with rheumatoid arthritis in the Kingdom of Saudi Arabia.
Al-Abdulkarim H; Sharma Y; Attar SM; Husain W; Al-Homood I; Al Omari B; Mohamed O; Alsaqa'aby M; Jaheen AM; Anwar A; Hamad TM; Alzahrani Z
J Med Econ; 2024; 27(1):134-144. PubMed ID: 38163926
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
[TBL] [Abstract][Full Text] [Related]
7. Tofacitinib in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in China: A Cost-Effectiveness Analysis Based on a Mapping Algorithm Derived from a Chinese Population.
Tan C; Li S; Yi L; Zeng X; Peng L; Qin S; Wang L; Wan X
Adv Ther; 2021 May; 38(5):2571-2585. PubMed ID: 33837917
[TBL] [Abstract][Full Text] [Related]
8. Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France.
Ghabri S; Binard A; Pers YM; Maunoury F; Caro JJ
Value Health; 2020 Apr; 23(4):461-470. PubMed ID: 32327163
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
Jansen JP; Incerti D; Mutebi A; Peneva D; MacEwan JP; Stolshek B; Kaur P; Gharaibeh M; Strand V
J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China.
Tian L; Xiong X; Guo Q; Chen Y; Wang L; Dong P; Ma A
Pharmacoeconomics; 2020 Dec; 38(12):1345-1358. PubMed ID: 32929677
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Biosimilars vs Leflunomide in Patients With Rheumatoid Arthritis.
Peng K; Chan SCW; Wang Y; Cheng FWT; Yeung WWY; Jiao Y; Chan EWY; Wong ICK; Lau CS; Li X
JAMA Netw Open; 2024 Jun; 7(6):e2418800. PubMed ID: 38922614
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.
Soini EJ; Hallinen TA; Puolakka K; Vihervaara V; Kauppi MJ
J Med Econ; 2012; 15(2):340-51. PubMed ID: 22168785
[TBL] [Abstract][Full Text] [Related]
15. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
[TBL] [Abstract][Full Text] [Related]
16. Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bermejo I; Stevenson M; Archer R; Stevens JW; Goka E; Clowes M; Scott DL; Young A
Pharmacoeconomics; 2017 Nov; 35(11):1141-1151. PubMed ID: 28550592
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis.
Alemao E; Johal S; Al MJ; Rutten-van Mölken M
Value Health; 2018 Feb; 21(2):193-202. PubMed ID: 29477401
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan.
Tanaka E; Inoue E; Yamaguchi R; Shimizu Y; Kobayashi A; Sugimoto N; Hoshi D; Shidara K; Sato E; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
Mod Rheumatol; 2017 Mar; 27(2):227-236. PubMed ID: 27472516
[TBL] [Abstract][Full Text] [Related]
19. Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bermejo I; Ren S; Simpson E; Clowes M; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Dec; 36(12):1427-1437. PubMed ID: 29882210
[TBL] [Abstract][Full Text] [Related]
20. UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug.
Kielhorn A; Porter D; Diamantopoulos A; Lewis G
Curr Med Res Opin; 2008 Sep; 24(9):2639-50. PubMed ID: 18687164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
